Pityriasis rubra pilaris following booster dose of <scp>mRNA</scp> (Pfizer– <scp>BioNTech</scp> ) <scp>COVID</scp> ‐19 vaccine

Data on various cutaneous adverse events as a result of widespread SARS-CoV-2 vaccination is currently accumulating. However, data on cutaneous reactions following booster dose of COVID-19 vaccines are still limited.1, 2 Herein, we present a case of pityriasis rubra pilaris (PRP) following a booster dose of the BNT163b2 (Pfizer–BioNTech) mRNA COVID-19 vaccine.